


Listing of Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.


1. (Cancelled)
2. (Currently Amended) A compound of formula (I),



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein


R^1 is C_{1-6} alkyl

R^2 is hydrogen or hydroxy or taken together with R^4 may form $=O$;

R^4 is hydrogen, C_{1-6} alkyl, furanyl, pyridinyl, aryl C_{1-6} alkyl -or -  ;

n is 0 or 1;

X is N or CR^5 , wherein R^5 is hydrogen;




R^3 is $-(CH_2)_s-$ NR^6R^7 or is ~~Z~~ (c-4);

s is 0, 1 or 2;

R^6 is $-CHO$, C_{1-6} alkyl, piperidinyl C_{1-6} alkyl, arylcarbonylpiperidinyl C_{1-6} alkyl or aryl C_{1-6} alkyl(C_{1-6} alkyl)amino C_{1-6} alkyl;

R^7 is hydrogen or C_{1-6} alkyl;


~~when R^3 is Z , then Z is a heterocyclic ring system selected from (c-2) or (c-4);~~



and each R^{10} independently is hydrogen, C_{1-6} alkyl or C_{1-6} alkyloxy C_{1-6} alkylamino,

aryl is phenyl or phenyl substituted with halo, C₁₋₆alkyl or C₁₋₆alkyloxy;

with the provision that when




n is 0, X is N, R² is hydrogen, R³ is (c-4) ~~Z, Z is the heterocyclic ring system (c-4)~~
~~wherein said heterocyclic ring system Z and~~ is attached with a nitrogen atom, and R¹⁰ is
hydrogen; then

R⁴ is other than C₁₋₆alkyl or pyridinyl.

3. (Previously Presented) A compound according to claim 2 wherein
n is 0; X is N or CR⁵, wherein R⁵ is hydrogen; R¹ is C₁₋₆alkyl;
R² is hydrogen or hydroxy or taken together with R⁴ may form =O; R³ is -(CH₂)_s- NR⁶R⁷;

s is 0 or 1; R⁶ is -CHO or C₁₋₆alkyl; and R⁴ is hydrogen, C₁₋₆alkyl or



4. (Previously Presented) A compound selected from the group consisting of:

<p>compound 1</p>	<p>compound 5</p>
<p>compound 7</p>	<p>compound 3</p>
<p>compound 17</p>	

and the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof.


5. (Cancelled)

6. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 2.


7. -11. (Cancelled).

12. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of formula (I) according to Claim 2.


13. (Previously Presented) A process for preparing a compound as claimed in claim 2, comprising: a) hydrolysis of intermediates of formula (VIII),



b) cyclization of intermediates of formula (X),



or c) condensation of an ortho-benzenediamine of formula (XI) with an ester of formula (XII) wherein R^h is C₁₋₆alkyl, into compounds of formula (I), wherein X is N, herein referred to as compounds of formula (I-i),



14. (Cancelled)

15. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 3.

16. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 4.


17. - 26. (Cancelled)

27. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 3.

28. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 4.

29. - 30. (Cancelled)

31. (Previously Presented) A compound selected from



and the *N*-oxide forms and the pharmaceutically acceptable addition salts thereof.

32. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 31.

33. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 31.